Vanos

Vanos is a brand name of fluocinonide topical, approved by the FDA in the following formulation(s):

VANOS (fluocinonide - cream; topical)

• 
  Manufacturer: MEDICIS
  
  Approval date: February 11, 2005
  
  Strength(s): 0.1% ^[RLD]

Has a generic version of Vanos been approved?

No. There is currently no therapeutically equivalent version of Vanos available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vanos. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Compositions and methods for enhancing corticosteroid delivery
  Patent 6,765,001
  Issued: July 20, 2004
  Inventor(s): Eugene H.; Gans & Mitchell S.; Wortzman
  Assignee(s): Medicis Pharmaceutical Corporation
  The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.
  
  Patent expiration dates:
  
  
  • December 21, 2021
    
    ✓ 
    Drug product
  
  



• 
  Compositions and methods for enhancing corticosteroid delivery
  Patent 7,220,424
  Issued: May 22, 2007
  Inventor(s): Gans; Eugene H. & Wortzman; Mitchell S.
  Assignee(s): Medicis Pharmaceutical Corporation
  The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.
  
  Patent expiration dates:
  
  
  • January 7, 2023
    
    ✓ 
    Patent use: RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
  
  



• 
  Compositions and methods for enhancing corticosteroid delivery
  Patent 7,794,738
  Issued: September 14, 2010
  Inventor(s): Gans; Eugene H. & Wortzman; Mitchell S.
  Assignee(s): Medicis Pharmaceutical Corporation
  The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.
  
  Patent expiration dates:
  
  
  • September 11, 2022
    
    ✓ 
    Patent use: RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
  
  

See also...

• Vanos Cream Consumer Information (Wolters Kluwer)
• Vanos Consumer Information (Cerner Multum)
• Vanos Advanced Consumer Information (Micromedex)
• Fluocinonide Cream Consumer Information (Wolters Kluwer)
• Fluocinonide Gel Consumer Information (Wolters Kluwer)
• Fluocinonide Solution Consumer Information (Wolters Kluwer)
• Fluocinonide topical Consumer Information (Cerner Multum)
• Lidemol Advanced Consumer Information (Micromedex)
• Lyderm Advanced Consumer Information (Micromedex)
• Tcis Advanced Consumer Information (Micromedex)
• Tiamol Advanced Consumer Information (Micromedex)
• Topsyn Advanced Consumer Information (Micromedex)
• Trisyn Advanced Consumer Information (Micromedex)
• Fluocinonide Topical application Advanced Consumer Information (Micromedex)